Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
Tarsus Pharmaceuticals, Inc. (TARS) had Receiveable Turnover of 0.98 for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
$17.45M |
|
$-135.89M |
|
$1.59M |
|
$15.85M |
|
$160.60M |
|
$-143.16M |
|
$7.26M |
|
$-135.89M |
|
$-135.89M |
|
$-135.89M |
|
$-135.89M |
|
$-135.89M |
|
$-135.89M |
|
$-143.16M |
|
$-145.06M |
|
29.38M |
|
29.38M |
|
$-4.62 |
|
$-4.62 |
|
| Balance Sheet Financials | |
$256.13M |
|
$1.47M |
|
$9.36M |
|
$265.49M |
|
$36.94M |
|
$29.82M |
|
$31.57M |
|
$68.50M |
|
$196.99M |
|
$193.12M |
|
$196.99M |
|
34.21M |
|
| Cash Flow Statement Financials | |
$-117.49M |
|
$140.60M |
|
$130.18M |
|
$71.66M |
|
$224.95M |
|
$153.29M |
|
$19.83M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.93 |
|
-- |
|
-- |
|
0.13 |
|
0.15 |
|
90.87% |
|
-820.53% |
|
-820.53% |
|
-831.43% |
|
-778.89% |
|
-778.89% |
|
$-119.00M |
|
-- |
|
-- |
|
-- |
|
0.07 |
|
0.51 |
|
|
Receiveable Turnover |
0.98 |
370.59 |
|
-68.99% |
|
-70.37% |
|
-51.19% |
|
-59.92% |
|
$5.76 |
|
$-4.05 |
|
$-4.00 |
|